Circulating TFH cells as a marker for early therapeutic intervention in T1D

Circulating TFH cells as a marker for early therapeutic intervention in T1D

Costimulatory blockade via the CTLA-4–Ig fusion protein abatacept is beneficial in patients with early-onset type 1 diabetes, but some individuals benefit more than others. A new study reports that the pretreatment abundance of T follicular helper (T FH ) cells could predict clinical responses to ab...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Nature immunology 2020-10, Vol.21 (10), p.1141-1142
Hauptverfasser: Bettelli, Estelle, Campbell, Daniel J.
Format: Artikel
Sprache:eng
Schlagworte:
631/250/1619/554/1898/1270
631/250/251/1574
631/250/38
Age
Biomedical and Life Sciences
Biomedicine
CTLA-4 protein
Diabetes mellitus (insulin dependent)
Fusion protein
Immunoglobulins
Immunology
Infectious Diseases
News & Views
news-and-views
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Costimulatory blockade via the CTLA-4–Ig fusion protein abatacept is beneficial in patients with early-onset type 1 diabetes, but some individuals benefit more than others. A new study reports that the pretreatment abundance of T follicular helper (T FH ) cells could predict clinical responses to abatacept.
ISSN:1529-2908
1529-2916
DOI:10.1038/s41590-020-0766-6